- heading up our In vivo pharmacology within diabetes, cardiovascular & kidney disease (team size: 46)- chair of our early innovation bringing new target projects into our research pipeline

Director of Cardiovascular Research- In vitro and in vivo pharmacology support of cardiovascular disease targets up to non-clinical development. Chairman of CVD 'focus group' - Target identification and evaluation of internal and external opportunities- driving drug discovery innovation and mature early ideas into valid projects.

Director of Diabetes & Cardiovascular Pharmacology- In vitro and in vivo pharmacology support of type 2 diabetes and cardiovascular disease targets up to non-clinical development. Type 2 Diabetes target Portfolio Manager- Target discovery and evaluation of internal and external opportunities

Director of Diabetes Biology- In vitro pharmacology support of type 2 diabetes and cardiovascular disease targets up to non-clinical development.

MethylDetect, a small Danish biotech offering ready-to-use kits for detection of aberrant gene methylation. The method has its use within basic research as well as potential biomarkers, e.g. in oncology.

EpiTherapeutics was a biotech company focused on drug discovery and development in the field of oncology. First-in-class, selective small molecule inhibitors of the epigenetic class of histone demethylases has been developed and progressed into late pre-clinical development. In May 2015 Gilead Sciences acquired EpiTherapeutics.Achievements at EpiTherapeutics: • Build efficient & lean R&D organization with majority of activities outsourced yet maintaining full control from office (17 FTE’s in house (15 Ph.D), 8 non-clinical/clinical consultants. Outsourced: 10 FTE chemists (7 Ph.D) and a flexible number of FTE’s for DMPK, in vitro biology, in vivo biology, CMC and toxicology).• Facilitated strong communication between disciplines (biology, chemistry, pre-clinical and clinical development)• Validation of new targets to pipeline• Pushed small molecule inhibitors from hit identification to clinical candidate nomination and development• Clear communication of science to Board of Directors, investors as well as in BD relations Main responsibilities & tasks at EpiTherapeutics:• Oversee all RD activities. Ensure speed & focus toward goals • Strategic decisions to chemistry, biology and development• Ensure execution of corporate strategy • Direct involvement in research programs, including external collaborations and IPR• Initially, responsible for development program, KOL interactions etc.• Responsible for preclinical toxicology and safety pharmacology• Responsible for due diligences

7TM Pharma was a biotech company focusing on discovery and development of new drugs targeting GPCR receptors. 7TM Pharma’s primary therapeutic area was metabolic diseases, including obesity & diabetes and cardiovascular diseases. 7TM pharma progressed three compounds (peptides & small molecules – agonists & antagonists) from target validation into clinical development.Achievements at 7TM Pharma: • Forming efficient pharmacology department, ensuring instant and full biology support for the in-house drug discovery programs• Full pharmacology assessment (in vitro & in vivo) and selection of candidates for pre-clinical nomination and documentation for IND filing • Established interdisciplinary data-management system• Performed site-closure (7TM in Hørsholm, CareX in Strasbourg)Main responsibilities & tasks at 7TM Pharma • Focus on strong interdisciplinary relationship between departments such as Biology, Chemistry, Computational Chemistry, ADME, data management • Managing department, broad HR experience (recruitment, resign, personal development of employees, salary/warrants, motivation of employees etc.)• Collaborations with external pharma partners, company acquisition, due diligence, project transfer • Project leader on several programs• IPR• Science insight into acquired metabolic diseases such as obesity, diabetes, cachexia, gastro-intestinal diseases

• Running an efficient in vitro pharmacology department, ensuring instant cellular data for the in-house drug discovery programs (GPCRs)• Managing department, HR experience • Assay development

Post doc. in William F. DeGrado’s lab, Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia.